Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease...

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Genetics

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder causing severe hypercholesterolemia and premature coronary artery disease (CAD).
• CAD presentation in FH patients is variable, suggesting non-LDL factors influence cardiovascular risk.
• High-density lipoprotein (HDL) plays a crucial role in reverse cholesterol transport and possesses anti-inflammatory and antioxidant properties.

Purpose of the Study:

• To investigate the role of HDL-associated proteins as additional factors contributing to cardiovascular risk in familial hypercholesterolemia.
• To identify specific HDL protein alterations linked to clinical manifestations and prognosis in FH patients.

Main Methods:

• Analysis of HDL-associated proteins in familial hypercholesterolemia patients.
• Correlation of protein levels with cholesterol efflux capacity, clinical features (corneal arcus), and prognosis after ischemic events.

Main Results:

• Specific changes in HDL-associated proteins, including Apo M-SP1, Apo L1, and LCAT, were observed in FH patients.
• Decreased Apo M-SP1 in HDL3 was associated with reduced cholesterol efflux capacity.
• Reduced Apo L1 and LCAT in HDL3 correlated with corneal arcus and poorer prognosis post-ischemia.
• HDL3 particles from FH patients exhibited diminished antioxidant and anti-inflammatory functions.

Conclusions:

• Alterations in HDL-associated proteins are significant contributors to the elevated cardiovascular risk in familial hypercholesterolemia.
• Targeting these specific HDL protein changes could lead to novel therapeutic strategies.
• Such strategies, combined with existing lipid-lowering therapies, may mitigate residual cardiovascular risk in FH patients.